• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AGN

ARGENICA THERAPEUTICS LIMITED

0.00% ! 25.0¢
Market Cap $32.11M  !
Healthcare Biotechnology
Add to My Watchlist

Argenica Therapeutics Limited is an Australia-based biotechnology company, developing... Argenica Therapeutics Limited is an Australia-based biotechnology company, developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischemic encephalopathy (HIE). The Company has completed a Phase I clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. It has completed dosing in a Phase II clinical trial in ischaemic stroke patients and continues to generate preclinical data in other neurological conditions, including in TBI and HIE.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
AGN
Ann: Final Director's Interest Notice 		12/11/25 0 136
12/11/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  136 
AGN
Ann: Results of Annual General Meeting 		12/11/25 0 108
12/11/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  108 
AGN
Ann: AGM Chair's Address & Presentation 		12/11/25 0 175
12/11/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  175 
AGN
Ann: Non-Executive Director Retirement 		12/11/25 0 166
12/11/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  166 
AGN
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes 		11/11/25 58 6.7K
11/11/25 Last post  Scottsmyname Comments Created with Sketch.  58  Views Created with Sketch.  6.7K 
AGN
Company Podcast 		04/11/25 2 473
04/11/25 Last post  Scottsmyname Comments Created with Sketch.  2  Views Created with Sketch.  473 
AGN
AGN Media thread
8 9 10
01/11/25 553 168K
01/11/25 Last post  BlueJ Comments Created with Sketch.  553  Views Created with Sketch.  168K 
AGN
Ann: Quarterly Activities/Appendix 4C Cash Flow Report 		31/10/25 0 180
31/10/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  180 

See All Discussions arrow Created with Sketch.

Timeline

Final Director's Interest Notice
12 Nov 19:05
 
Results of Annual General Meeting
12 Nov 19:03
 
AGM Chair's Address & Presentation
12 Nov 16:53
 
Non-Executive Director Retirement
12 Nov 16:49
 
Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 09:16
 
Investor Presentation - Cannacord Dug & Device Conference
21 Oct 09:04
 
View More arrow Created with Sketch.

Featured News

NEWS View the latest ASX news here
right-arrow Created with Sketch.
NEWS Webjet nosedives on lower domestic travel demand; blames just about everything
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast – Is lithium back?
right-arrow Created with Sketch.
NEWS Investor fury as DroneShield sinks -33% after CEO sells all shares at ~$3.30
right-arrow Created with Sketch.
NEWS Renerve pops +80% as US defence, veterans affairs depts approve nerve healing product
right-arrow Created with Sketch.
NEWS Commonwealth dumps in W46 after market really didn't like Comyn's 'copycat competitors' claims
right-arrow Created with Sketch.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
25.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $32.11M
Open High Low Value Volume
24.5¢ 25.0¢ 24.5¢ $59.67K 242.0K

Buyers (Bids)

No. Vol. Price($)
1 18513 24.5¢
 

Sellers (Offers)

Price($) Vol. No.
25.0¢ 51404 1
View Market Depth
Last trade - 15.55pm 14/11/2025 (20 minute delay) ?
AGN (ASX) Chart

Top Stories

Week 46 Wrap: I feel like the Santa Rally isn't going to happen this year either. Also, Simandou is here

Well, what a week it’s been. The ASX200 is back down to the 8,640s as I write this (at 2.25pm AEDT) and that means 1Y returns for the index are down to +5%. Not that long ago, the XJO was looking at YTD returns of +10% when the US-Australia critical minerals deal was the flavour o...
Redcastle kicks off gold drilling in WA, with first assays due back by year's end Redcastle Resources has kicked off a 2,700 metre RC drill run on-site at its Western Australian "MCE and Sligo Gold Targets" at RPA.
Long life, great estimates: WIN Metals celebrating Butchers Creek 'viability' after key scoping study WIN Metals has shared blockbuster news in Week 45, confirming its Butchers Creek project is "viable" through a key scoping study.
Listen: HotCopper Wire Podcast 031 – Is lithium back? In this HotCopper Wire W46 episode, we talk about lithium's supposed revival (especially with how the spodumene prices have been tracking).
HotCopper Highlights: Droneshield, what the hell? Plus MinRes' $1B steal; Life360 & more Good Afternoon and welcome to HotCopper Highlights for Week 46, I’m Jon Davidson. In this segment the stocks you were watching and discussing the most this week, for better or worse @ let’s get into it starting with the most viewed.Listen to the HotCopper podcast f...

Featured News

NEWS Renerve pops +80% as US defence, veterans affairs depts approve nerve healing product
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast – Is lithium back?
right-arrow Created with Sketch.
LM1 New Gold Hits Extend Marda Trend for Leeuwin
right-arrow Created with Sketch.
NEWS View the latest ASX news here
right-arrow Created with Sketch.
NEWS Commonwealth dumps in W46 after market really didn't like Comyn's 'copycat competitors' claims
right-arrow Created with Sketch.
NEWS Webjet nosedives on lower domestic travel demand; blames just about everything
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.